Empirical Financial Services, LLC D.B.A. Empirical Wealth Management Corvus Pharmaceuticals, Inc. Transaction History
Empirical Financial Services, LLC D.B.A. Empirical Wealth Management
- $4.91 Billion
- Q3 2025
A detailed history of Empirical Financial Services, LLC D.B.A. Empirical Wealth Management transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Empirical Financial Services, LLC D.B.A. Empirical Wealth Management holds 169,200 shares of CRVS stock, worth $1.48 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
169,200
Previous 168,000
0.71%
Holding current value
$1.48 Million
Previous $672,000
80.21%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding CRVS
# of Institutions
109Shares Held
38.3MCall Options Held
198KPut Options Held
167K-
Orbimed Advisors LLC San Diego, CA7.17MShares$62.8 Million1.75% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.45MShares$56.6 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$30.4 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$28.7 Million16.52% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$23.5 Million0.26% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $408M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...